Despite its well-described safety and efficacy in the treatment of sickle cell anemia (SCA) in highincome settings, hydroxyurea remains largely unavailable in sub-Saharan Africa, where more than 75% of annual SCA births occur and many comorbidities exist. Realizing Effectiveness Across Continents with Hydroxyurea (REACH, ClinicalTrials.gov NCT01966731) is a prospective, Phase I/II open-label trial of hydroxyurea designed to evaluate the feasibility, safety, and benefits of hydroxyurea treatment for children with SCA in four sub-Saharan African countries. Following comprehensive training of local research teams, REACH was approved by local Ethics Committees and achieved full enrollment ahead of projections with 635 participants enrolled over a 30-month period, despite half of families living >12 km from their clinical site. At enrollment, study participants (age 5.4 6 2.4 years) had substantial morbidity, including a history of vaso-occlusive pain (98%), transfusion (68%), malaria (85%), and stroke (6%). Significant differences in laboratory characteristics were noted across sites, with lower hemoglobin concentrations (P < .01) in Angola (7.2 6 1.0 g/dL) and the DRC (7.0 6 0.9 g/dL) compared to Kenya (7.4 6 1.1 g/dL) and Uganda (7.5 6 1.1 g/dL). Analysis of known genetic modifiers of SCA demonstrated a high frequency of a-thalassemia (58.4% with at least a single a-globin gene deletion) and G6PD deficiency (19.7% of males and 2.4% of females) across sites. The CAR b-globin haplotype was present in 99% of participants. The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa.
living in the region. Although the benefits of hydroxyurea are well proven in high-income settings, [12] [13] [14] [15] [16] [17] [18] [19] there are virtually no data regarding the feasibility, dosing, or safety of hydroxyurea treatment in subSaharan Africa. 3 Despite experiences demonstrating that the benefits of hydroxyurea are optimized when the dose is escalated to maximum tolerated dose (MTD), 13, 20 it is unclear if MTD is practical in low and middle income settings or whether lower doses may be the best option in clinical settings where resources for monitoring dosing and toxicity are limited. [21] [22] [23] Realizing Effectiveness Across Continents with Hydroxyurea (REACH, ClinicalTrials.gov NCT01966731) is a prospective, phase I/II open-label dose escalation trial of hydroxyurea in four sub-Saharan
African countries designed to evaluate the safety, dosing, feasibility, and benefits of hydroxyurea for children with SCA. 24 An important objective of the study is to gather local evidence in African settings, such that dosing and laboratory monitoring guidelines can be developed to increase availability of and access to hydroxyurea for the hundreds of thousands of children who desperately need it. In addition to investigating practical clinical outcomes, REACH also aims to develop local research capacity within a strong collaborative international research network. 3 We now report the successful full enrollment of the REACH trial, and provide descriptions of the baseline characteristics of this large and multi-national study population. bodies, at all four clinical sites. The rationale and details of the study design have been previously published. 24 REACH aimed to enroll 150 participants per site, which gives 90% power in a Simon two-stage design to show the frequency of dose-limiting cytopenias (the primary safety endpoint) is less than 30% if the true rate is 20%. Patients were recruited locally and selected from the large clinical population at each site, at the discretion of the local lead investigators. Each site had substantially more eligible patients than the study could enroll, and therefore chose which patients to recruit. Inclusion/exclusion criteria were intentionally broad requiring only a diagnosis of SCA and a lack of concurrent chronic diseases or severe malnutrition (z-score <-3). There was purposefully no specification in regard to the frequency or severity of SCA complications, allowing local site investigators the ability to select participants with the most need for hydroxyurea, including patients with the highest clinical severity or the highest socioeconomic need (ie, those who could not afford hydroxyurea if purchased outside of the study). Three sites provided group education early in the study recruitment period about hydroxyurea treatment and the REACH study to garner interest among their patient population and subsequently, approached families on an individual basis as they were seen at the clinic or hospital with acute complications of SCA.
| M E TH ODS

| Study overview
Upon enrollment, participants entered a 2-month screening period to confirm study treatment eligibility, document adherence to clinic visits, and provide pretreatment laboratory data and clinical events. Three of the four sites agreed that nominal reimbursement for travel was beneficial, while one site (Site 1) determined that enrollment in the study and the receipt of hydroxyurea was sufficient reimbursement and that travel reimbursement might create additional advantages from the rest of their large patient population. Study participants then entered a hydroxyurea treatment phase at a fixed dose of 20 mg/kg/ day, which was maintained for six months before escalating to MTD based on prespecified laboratory criteria. 24 The study, which is still ongoing, will continues to a common termination date, currently scheduled for four years from the time the first child initiated hydroxyurea treatment. 24 For each study participant, z-scores were calculated for height-for-age (HAZ), weight-for-height (WHZ), and weight-for-age (WAZ) using the WHO growth metrics. 25 HAZ is a measure of chronic malnutrition with values <-2 defined as stunting; WHZ is a measure of acute malnutrition with values <-2 defined as wasting; and WAZ is a less specific measure with values <-2 defined as underweight. Z-scores <-3 identify children with severe malnutrition and HAZ or WHZ<-3 was an exclusion criteria for REACH. Most study data were captured on paper, with primary source documents uploaded into the REDCap system to allow ongoing remote study monitoring, which helped ensure high quality and accurate study data. ). The b-globin haplotype was determined using a combination of TaqMan probes and restriction digestion patterns to identify the classical polymorphisms that distinguish the five common haplotypes. 28, 29 This method allowed for the detection of the Central
| Data collection and analysis
| Standardized laboratory methods
African Republic (CAR, also known as Bantu), Benin (BEN), Senegal (SEN), Cameroon (CAM), and Arab-Indian (ARAB) haplotypes.
| Statistical methods
Categorical and continuous data were summarized by frequency (percent) and mean (standard deviation), respectively. Differences in categorical variables between sites were assessed by the Chi-squared test when appropriate. In cases were the expected number for any cell was less than 5, a Fisher exact test was used in place of the Chi-squared test. Differences in continuous variables between sites were tested using one way ANOVA. All calculations were done in R (version 3.2.4).
| R E SU LTS
| Enrollment
With the goal of enrolling and screening enough children to treat 600 with hydroxyurea, REACH enrollment was brisk due to the large vol- or WHZ <-3 documenting severe malnutrition (n 5 2). The 9 nonadherent participants were removed from the study prior to starting hydroxyurea at the discretion of the local site lead investigators, due to concerns that they would not be able to attend the protocol-direct clinic visits reliably during the treatment phase of the study. Figure S2 illustrates the home location for each study participant, in reference to the clinical site.
| Demographics
| Past medical history and physical examination
Almost all enrolled children reported previous vaso-occlusive pain (98%) and dactylitis (80%), while 6% of the patients had previous stroke (Supporting Information Table S1 ). At the time of enrollment, >70% of study participants at each site reported a history of previous blood transfusion except at Site 3, where fewer children (46%) had a history of transfusion. Routine care at all sites included prophylactic penicillin for children <5 years of age and folic acid supplementation, though there were significant differences in malaria preventive measures. The reported use of bed nets was common (85%), but there were significant differences noted across sites with participants at Site 1 (69%) less likely to report use of bed nets compared to Site 2 (90%), Site 3 (80%), and Site 4 (99%). Routine malaria chemoprophylaxis was Table 2 summarizes the baseline laboratory characteristics for all 606 study participants who completed screening across the four clinical sites.
| Laboratory parameters
The laboratory values were generally as expected for untreated children with SCA, but some significant between-site differences were noted.
For example, the average hemoglobin concentration was significantly lower at Site 1 (7.2 g/dL) and Site 2 (7.0 g/dL), compared to Sites 3 (7.4 g/dL) and 4 (7.5 g/dL). Similarly, the baseline proportion of fetal hemoglobin was significantly higher at Site 4 than the other three clinical sites. There were additional small but significant differences in the baseline reticulocyte, leukocyte and neutrophil counts, and MCV (Table 2 ).
| Genetic modifiers
Adequate DNA was extracted from all FTA cards transported to CCHMC for genetic testing (Table 3) G6PD deficiency was common at all clinical sites, with the prevalence of affected hemizygous males ranging from 16 to 24% and heterozygous female carriers ranging from 27 to 39% (Table 3 , P < .01). There was a trend toward lower HbF for participants without any a-globin gene deletions compared to those with one or two deletions, but this was not statistically significant (P 5 .06). There were similar rates of a-globin gene deletions among the 34 participants with previous stroke. Participants with two a-globin gene deletions were significantly less likely (P < .01) to have previous blood transfusion (48%) than those with zero (70%) or one a-globin deletion (70%).
There were no differences in the reported history of malaria across the a-globin genotypes. The b-globin haplotype was almost exclusively 
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Central African Republic (CAR), with 92% of children having the homozygous CAR/CAR genotype; however, five children were identified with an Arab-Indian haplotype. Neither G6PD deficiency nor b-globin haplotype was associated with any significant differences in baseline laboratory values or reported clinical history.
| D I SCUSSION
The design of the REACH trial was ambitious, aiming to enroll and treat This degree of study retention is remarkable, especially when considering the effort required to attend the clinic for study visits, and the fact that many families have limited resources with challenging living conditions, multiple children, lack of reliable transportation, and long travel distances. Supporting Information Figure S2 shows that 40% of participants traveled more than 15 km each way for study visits, often by various forms of connecting public transportation. Feasibility for the subsequent treatment phase will be assessed through recording the frequency of attended clinic visits within the protocol-specified study windows.
These pretreatment REACH enrollment data allow comparisons among large cohorts of children with SCA across four countries in subSaharan Africa, with several important similarities and differences Given the large population of patients at each site eligible to enroll in the REACH study, local investigators chose to approach patients with more clinically severe phenotypes. Each clinical site had many patients who might benefit from hydroxyurea, and local investigators had discretion to determine which patients were offered enrollment. Similar to the Phase I/II HUG-KIDS trial in the US, REACH offered treatment to those with the highest clinical severity to boost enrollment and adherence, while providing potential benefit to sicker children. 30 The study purposefully provided relatively flexible inclusion and exclusion criteria, allowing local sites to determine which patients might benefit most from hydroxyurea therapy. This may have led to some selection bias that contributed to the differences in baseline characteristics among sites. Unsurprisingly, nearly all enrolled participants reported previous painful vaso-occlusive crises and malaria infection. The reported prevalence of each of these clinical diagnoses likely underestimates the actual value, however, given that this information was mostly obtained through parental self-report. Many diagnoses, such as acute chest syndrome, stroke, sepsis, and osteomyelitis require high clinical suspicion and advanced technology, which limits diagnostic accuracy in these resource-limited settings. Prophylactic treatment with penicillin were routinely prescribed at all sites and malaria chemoprophylaxis was prescribed at 2 of the 4 clinical sites, but adherence to these medications was not documented and may have been limited due to socioeconomic conditions. Most study participants also had received at least one blood transfusion, though Site 3 uses transfusions less frequently, due to decreased blood availability at this more rural site. As expected for untreated children with SCA living in low and middle-income countries, there was moderate malnutrition among most enrolled participants, with more wasting (lower WHZ) noted at Site 1 but more chronic malnutrition (lower HAZ) and underweight children (low WAZ) at Site 3.
The causes of these differences are not clear, but they may be important factors that influence the dosing, response, and toxicity of hydroxyurea therapy. It will also be important to carefully investigate how baseline nutritional differences contribute to these hydroxyurea parameters, and to monitor the effects of hydroxyurea therapy on these growth parameters over time.
Laboratory values revealed expected degrees of anemia and reticulocytosis, along with increased neutrophil and platelet counts. On average, however, the baseline hematological parameters demonstrated more severe anemia than age-matched patients in the US 31 and Jamaica, 32 with a mean baseline hemoglobin concentration of 7.3 g/dL across the entire trial. These baseline hematological parameters were consistent with those previously described for other children with SCA in sub-Saharan Africa. [33] [34] [35] There were several significant differences in baseline laboratory characteristics across sites ( Table 2 ) that are possibly due to differences in the unique genetic, nutritional, and environmental backgrounds at each of the four locations. There were statistically significant differences noted in both bilirubin and ARC that could reflect important differences in baseline levels of hemolysis, which will require prospective evaluation to determine if these participants require or tolerate higher doses of hydroxyurea. Reflecting the CAR b-globin haplotype, average fetal hemoglobin levels were only 10%-12% in these young cohorts (Table 2 ). This relatively low HbF starting point will allow prospective evaluation of the therapeutic benefits of hydroxyurea, both at the 15-20 mg/kg/day starting dose and after escalation to MTD in the subsequent treatment phase of the study.
Genetic analyses demonstrated the feasibility and utility of using dried bloodspots to isolate genomic DNA and perform several genotyping assays. Despite variation in local collection practices and storage conditions, DNA was successfully extracted from nearly all dried blood spot samples with evaluable results for all molecular assays performed.
Despite a given diagnosis of homozygous HbSS for all participants, genetic analyses identified an unexpected diagnosis of HbS/b 0 -thalassemia for 11 REACH participants (1.8%), which has been rarely described in sub-Saharan Africa. 36, 37 The finding that eight children at Site 3 carry the same null b-globin mutation suggests a founder effect, whose origin and migration patterns remain to be elucidated. This is a novel finding that deserves further investigation to determine the inci- -thalassemia should be considered for patients with elevated %HbA 2 and decreased MCV. As previously described, [38] [39] [40] there was a high frequency of both athalassemia and G6PD deficiency in our cohort, which may ameliorate the risk of severe malaria [41] [42] [43] and sickle phenotype, [44] [45] [46] [47] [48] [49] [50] but may also affect the responses to hydroxyurea therapy. 51 Study participants with two a-globin gene deletions had significantly higher hemoglobin con- 
